



November 11, 2025

BSE Ltd.
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai 400 001

BSE Scrip Code : 506943

Stock Symbol: JBCHEPHARM

Dear Sir,

Subject: Press Release

Enclosed please find press release the Company proposes to issue on unaudited consolidated financial results for the quarter ended on September 30, 2025.

Kindly take the same on record.

Thanking you,

Yours faithfully,

For J.B. Chemicals & Pharmaceuticals Limited

**Sandeep Phadnis
Vice President - Secretarial
& Company Secretary**

Registered Office:

J.B. Chemicals & Pharmaceuticals Limited,
CIN: L24390MH1976PLC019380
Neelam Centre, 'B' Wing, 4th Floor, Hind Cycle Road,
Worli, Mumbai – 400030, T:+91 22 24822222

Corporate Office:

J.B. Chemicals & Pharmaceuticals Limited,
CIN: L24390MH1976PLC019380
Cnergy IT Park, Unit A, 8th Floor, Appa Saheb Marathe Marg,
Prabhadevi, Mumbai – 400025, T:+91 22 24395200/5500
secretarial@jbpharma.com

www.jbpharma.com



Press Release

JB Pharma records revenue growth of 8% to INR 1085 crores in Q2 FY26 Operating EBITDA increased by 12% to INR 319 crores Net Profit increases by 19% to INR 208 crores

Mumbai, India; November 11, 2025 – JB Chemicals & Pharmaceuticals Ltd (JB Pharma), one of the fastest growing pharmaceutical companies in India, announced its financial results for the quarter ended 30th September 2025.

Quarterly Financial Performance – Q2 FY26 vs Q2 FY25

JB Pharma recorded revenue of INR 1,085 crores in the second quarter of FY26, registering growth of 8% from INR 1,001 crores in Q2 FY25. Operating EBITDA* (Earnings before Interest, Depreciation and Taxes) increased by 12% to INR 319 crores compared to INR 285 crores in the same quarter last year. Net Profit rose by 19% to INR 208 crores versus INR 175 crores in Q2 FY25.

*Operating EBITDA is after excluding non-cash ESOP charge and one off charges

Commenting on the financial results, **Mr. Nikhil Chopra, CEO and Wholetime Director, JB Pharma stated** *“JB’s domestic business continued to outperform the market, with all major brands delivering robust growth. Our focus on driving steady volume growth across key brands — including recently acquired portfolios — continues to yield good results. On the international front, momentum in our CDMO business has returned, supported by a solid order book that positions us for further growth in the second half of the year.*

Over the years, JB has consistently delivered strong revenue and margin performance. We are confident in sustaining this positive momentum as we progress toward our operational and strategic goals for the current year and beyond. As we chart the path ahead, our focus remains on building a progressive, agile, and future-ready organization.”

Registered Office:

J.B. Chemicals & Pharmaceuticals Limited,
CIN: L24390MH1976PLC019380
Neelam Centre, 'B' Wing, 4th Floor, Hind Cycle Road,
Worli, Mumbai – 400030, T:+91 22 24822222

Corporate Office:

J.B. Chemicals & Pharmaceuticals Limited,
CIN: L24390MH1976PLC019380
Cnergy IT Park, Unit A, 8th Floor, Appa Saheb Marathe Marg,
Prabhadevi, Mumbai – 400025, T:+91 22 24395200/5500

www.jbpharma.com



GOOD PEOPLE
for GOOD HEALTH

Financial Performance – H1 FY26 vs H1 FY25

For the first half of the financial year 2025-26, the Company recorded revenue of INR 2179 crores as compared to INR 2005 crores, registering growth of 9%. Operating EBITDA* (Earnings Before Interest Depreciation and Taxes) increased by 13% to INR 649 crores as compared to INR 576 crores. Profit after Tax registered growth of 17% to INR 410 crores vs INR 351 crores in H1 FY25.

Financial Performance

Q2 FY26 vs Q2 FY25

Particulars (INR Crores)	Q2 FY26	Q2 FY25	YoY Growth
Revenue	1085	1001	8%
Operating EBITDA*	319	285	12%
Op. EBITDA Margin (%)	29.4%	28.4%	
Profit Before Tax	279	237	18%
Profit After Tax	208	175	19%

H1 FY26 vs H1 FY25

Particulars (INR Crores)	H1 FY26	H1 FY25	YoY Growth
Revenue	2179	2005	9%
Operating EBITDA*	649	576	13%
Op. EBITDA Margin (%)	29.8%	28.7%	
Profit Before Tax	551	476	16%
Profit After Tax	410	351	17%

Sales Performance

Q2 FY26 vs Q2 FY25

Particulars (INR Crores)	Q2 FY26	Q2 FY25	YoY Growth
Domestic Formulations	644	588	9%
International Formulations	441	413	7%
Total Revenue	1085	1001	8%

Registered Office:

J.B. Chemicals & Pharmaceuticals Limited,
CIN: L24390MH1976PLC019380
Neelam Centre, 'B' Wing, 4th Floor, Hind Cycle Road,
Worli, Mumbai – 400030, T:+91 22 24822222

Corporate Office:

J.B. Chemicals & Pharmaceuticals Limited,
CIN: L24390MH1976PLC019380
Cnergy IT Park, Unit A, 8th Floor, Appa Saheb Marathe Marg,
Prabhadevi, Mumbai – 400025, T:+91 22 24395200/5500

www.jbpharma.com



GOOD PEOPLE
for **GOOD HEALTH**

H1 FY26 vs H1 FY25

Particulars (INR Crores)	H1 FY26	H1 FY25	YoY Growth
Domestic Formulations	1322	1183	12%
International Formulations	857	822	4%
Total Revenue	2179	2005	9%

Key Highlights

Q2 FY26 vs Q2 FY25

- JB Pharma's revenue grew 8% to INR 1085 crores vs INR 1001 crores
- Domestic formulations business recorded revenue of INR 644 crores vs INR 588 crores (YoY growth of 9%)
 - The chronic as well as the acute segments performed well
 - All the progressive brands and their respective franchises recorded good growth
- International business revenue grew by 7% at INR 441 crores vs INR 413 crores
 - International formulations business showed stable performance and is on track to pick up in H2; the CDMO division delivered strongly and remains backed by a robust order book

Financial Overview Q2 FY26 vs Q2 FY25

- Operating EBITDA grew by 12% to INR 319 crores vs INR 285 crores
 - Operating EBITDA margin was at 29.4% vs 28.4%
 - Operating EBITDA margin for H1 FY26 was 29.8% vs 28.7% for H1 FY25
- Gross margin increased by 200 bps to 68.2% vs 66.2%
 - Cost optimization efforts, favorable product mix and price growth positively impacted gross margin
- Overheads expenditure including employee cost have been kept under control which has aided operating margins
 - Freight costs continue to remain escalated for international business
- Depreciation expenses increased marginally to INR 44 crores
- Net Profit improved by 19% to INR 208 crores vs INR 175 crores

Registered Office:

J.B. Chemicals & Pharmaceuticals Limited,
CIN: L24390MH1976PLC019380
Neelam Centre, 'B' Wing, 4th Floor, Hind Cycle Road,
Worli, Mumbai – 400030, T:+91 22 24822222

Corporate Office:

J.B. Chemicals & Pharmaceuticals Limited,
CIN: L24390MH1976PLC019380
Cnergy IT Park, Unit A, 8th Floor, Appa Saheb Marathe Marg,
Prabhadevi, Mumbai – 400025, T:+91 22 24395200/5500

www.jbpharma.com



Domestic Business Q2 FY26 vs Q2 FY25

- Domestic business continued its momentum and registered YoY growth of 9% to INR 644 crores
- Domestic business constitutes 61% of overall turnover in H1 FY26 as compared to 59% of revenue in H1 FY25
- JB Pharma continues to remain one of the fastest growing companies in the industry. As per IQVIA MAT Sep'25 data -
 - JB Pharma outperformed IPM and clocked YoY growth of 12% vs IPM growth of 8%
 - JB Pharma volume growth is 5% as compared to IPM volume growth of 1.3%
 - Razel franchise crosses INR 100 crores in sales
 - Razel franchise recorded growth of 12% to INR 104 crores
 - Our major brands viz. Cilacar, Cilacar-T, Metrogyl, Nicardia & Sporlac gained ranks as per IQVIA data
 - JB Pharma now has 3 brands among the top 100 brands in IPM

International Business Q2 FY26 vs Q2 FY25

- International business revenue grew at 7% to INR 441 crores vs INR 413 crores
- International formulations business grew by 2% to INR 306 crores
 - Russia market recorded strong growth for the quarter
 - The other markets remained subdued in the second quarter, and we expect growth to bounce back in H2 FY26
- CDMO business grew by 20% to INR 113 crores for Q2 FY26
 - Despite low base in Q2 FY25, CDMO sales growth momentum has been good
- API business recovered well and clocked revenue of INR 22 crores

About JB Pharma

J.B. Pharma (BSE: 506943 | NSE: JBCHEPHARM | ISIN: INE572A01028), established in 1976, is one of the fastest growing pharmaceutical companies in India and a leading player in the hypertension segment. Besides its strong India presence, which accounts for majority of its revenue, its other two home markets are Russia and South Africa. In India, the company has six brands among the top 300 IPM brands in the country. The company exports its finished formulations to over 40 countries including the USA. Besides supplying branded generic formulations to several countries, it is also a leader in the

Registered Office:

J.B. Chemicals & Pharmaceuticals Limited,
CIN: L24390MH1976PLC019380
Neelam Centre, 'B' Wing, 4th Floor, Hind Cycle Road,
Worli, Mumbai – 400030, T:+91 22 24822222

Corporate Office:

J.B. Chemicals & Pharmaceuticals Limited,
CIN: L24390MH1976PLC019380
Cnergy IT Park, Unit A, 8th Floor, Appa Saheb Marathe Marg,
Prabhadevi, Mumbai – 400025, T:+91 22 24395200/5500

www.jbpharma.com



GOOD PEOPLE
for **GOOD HEALTH**

manufacturing of medicated lozenges. The company ranks amongst the top 5 manufacturers globally in medicated and herbal lozenges. It has eight state of the art manufacturing facilities in India including a dedicated manufacturing facility for lozenges. The manufacturing facilities are certified by leading regulators across the world.

For more details on J.B. Pharma, please visit www.jbpharma.com

For details of our latest sustainability report, please visit <https://jbpharma.com/sustainability-report/>

Media Contact

Mr. Harsh Sheth

MSL Group

Tel: +91 9870631557

Email : harsh.sheth@mslgroup.com

Investor Contact

Mr. Sidharth Ragnekar / Ms. Shruti Joshi

CDR India

Tel : +91 976 991 9966/ +91 750 656 7349

Email : siddharth@cdr-india.com

Shruti@cdr-india.com

Registered Office:

J.B. Chemicals & Pharmaceuticals Limited,
CIN: L24390MH1976PLC019380
Neelam Centre, 'B' Wing, 4th Floor, Hind Cycle Road,
Worli, Mumbai – 400030, T:+91 22 24822222

Corporate Office:

J.B. Chemicals & Pharmaceuticals Limited,
CIN: L24390MH1976PLC019380
Cnergy IT Park, Unit A, 8th Floor, Appa Saheb Marathe Marg,
Prabhadevi, Mumbai – 400025, T:+91 22 24395200/5500



www.jbpharma.com